Science and Technology CBD Focus Areas - Biosurveillance

Biomonitoring focuses mainly on effective monitoring, prevention and operational capacity development to detect and respond to biological threats. S & T integrates information into a monitoring architecture using a system level approach, develops and tests advanced inspection systems, and performs cross domain attention to biological, chemical and agricultural threats.

The Enhanced Passive Monitoring Program is working to further develop, demonstrate and deliver conceptual demonstration monitoring systems to identify the occurrence of endemic endemic, borderless and newly occurring diseases in livestock. The expanded system can be used to determine baseline morbidity of observed animal health problems, track changes in animal health, and to identify trigger points that warn officials to take actions from different sources Integrate multiple monitoring data streams in real time.

The BioThreat Awareness APEX program develops affordable, efficient and fast detection systems and architecture to provide early warning of biological attacks indoors, outdoors, and national security incidents. In this project, the testing of integrated information sharing system also includes local jurisdiction to quickly deliver related data to important decision makers during the event.

The bio-monitoring information and knowledge integration program is a prototype of a practical community (COP) platform that integrates multiple data streams to support decision-making during biological events and to provide training tools to state counterparts It is designed to develop. This work focuses on New York City and is working on a nationwide implementation. By validating the workflow and developing the COP platform to include the highest priority information flow, it is possible not only to validate functions close to the ambitious series of stakeholder prototypes but also to enlarge the latency of other metropolitan areas It also functions as a template. By examining NYC biomonitoring, you will learn how to provide bio-defense solutions with limited resources and extreme levels of competitive information and priorities.

HITSP also conducts a similar review process on the health information community in the United States and has three key themes to bring innovative opportunities for healthy IT such as biomonitoring and consumer empowerment Select a field. Contractors at HHS develop use cases in these areas, but this also requires standard coordination. HITSP is operated under a three-year contract and can be updated every year for four consecutive years. Mr. Hallamka predicts "the team will talk about how to adjust the standards for competition and redundancy." Adjusting existing criteria will be a major part of the team's work. Halamka said that some requirements, such as exchanging drug lists, may be relatively simple, given that the number of standards used is relatively small.

This group will focus on how technology will help open science and its role in creative processes. Naturally, European scientists, ElPeriódico, other physicists and freelance science journalist Michele Catanzaro tried to understand the direction of academic world and how to involve more scholars into open science I will. This gender-balanced group consists of stakeholder research ecosystem representatives, including young and mature researchers, academic publishers, research policy assistants, and academic policy officers. We will discuss the already available and in-use resources, as well as the sharing of data, methods, and interpretations from open peer review to open access publishing, as well as further improvements needed to make open science a part of the research workflow.

Scientific research and ongoing (and predecessor) projects of CSIR - IMTECH enable technology development. The focus is science and technology related to microbial products. An important field is based on genetic recombination technology. One initiative involves the development of household thrombotics. The first attempt in the late 1980s focused on ubiquitous drugs, tissue plasminogen activator (tPA), which is ubiquitously present in humans in a small amount. Professor Collen and his organization Genentech USA have produced tPA from animal cell lines in the early 1980s by pioneering recombinant gene technology in this field. There are no partial results in attempts to reproduce tPA production at IMTECH because there is not enough scientists widely practicing the external environment and enough scientists to carry out this task.